OCGN Forex ziņas

Ocugen Receives Health Canada Approval To Initiate Phase 3 LiMeliGhT Trial For OCU400

Biotechnology company Ocugen, Inc. (OCGN) announced Monday that Health Canada provided a "No Objection Letter" to initiate the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).

RTTNews | 59 days ago

Noteikumi | Privātums | Lapas karte | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.08185	GBPUSD	1.29718	AUDUSD	0.6639
USDJPY	151.658	USDCAD	1.38497	USDCHF	0.86573